Vimpat FDA Approval History
Last updated by Judith Stewart, BPharm on Dec 16, 2021.
FDA Approved: Yes (First approved October 28, 2008)
Brand name: Vimpat
Generic name: lacosamide
Dosage form: Tablets, Injection, Oral Solution
Company: UCB, Inc.
Treatment for: Seizures
Vimpat (lacosamide) is an anti-convulsant indicated for the treatment of partial-onset seizures in patients 1 month of age and older, and the adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
Development timeline for Vimpat
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.